Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6083961,absorption loss,"This dose which amounts to 35.2 micrograms PPC per kg body weight will nearly be equal to the clinically used 3-mg dose related to a normal subject of 70 kg, if an absorption loss of 15 per cent is taken into consideration.",A pharmacokinetic model of the adjustment of phenprocoumon (Falithrom) dosage. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6083961/),%,15,4400,DB00946,Phenprocoumon
,6534380,t0.5 beta,"Under simultaneous administration of phytomenadion (PHY) in daily doses of 10 mg, the elimination of phenprocoumon (PPC) was not altered (t0.5 beta 141.4 h, CUE50 20.4% of administered dose) as compared with data of previous investigations, while its anticoagulant effect was inhibited.",Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),h,141.4,11689,DB00946,Phenprocoumon
,6534380,half-life,PHY in doses of 10 mg was absorbed quickly and eliminated with a mean half-life of 60.6 h at a total body clearance (Cltot) of 9.3 ml/min and a renal clearance (Clren) of 1.9 ml/min.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),h,60.6,11690,DB00946,Phenprocoumon
,6534380,total body clearance (Cltot),PHY in doses of 10 mg was absorbed quickly and eliminated with a mean half-life of 60.6 h at a total body clearance (Cltot) of 9.3 ml/min and a renal clearance (Clren) of 1.9 ml/min.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],9.3,11691,DB00946,Phenprocoumon
,6534380,renal clearance (Clren),PHY in doses of 10 mg was absorbed quickly and eliminated with a mean half-life of 60.6 h at a total body clearance (Cltot) of 9.3 ml/min and a renal clearance (Clren) of 1.9 ml/min.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],1.9,11692,DB00946,Phenprocoumon
,6534380,half-life time,Under the co-administration of PPC the vitamin was eliminated with a half-life time of 23.1 h (Cltot 16.7 ml/min) and the amount of excreted radioactivity was enhanced (26.3% of administered dose; Clren 4.5 ml/min) as compared with the data of PHY without co-medication.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),h,23.1,11693,DB00946,Phenprocoumon
,6534380,Cltot,Under the co-administration of PPC the vitamin was eliminated with a half-life time of 23.1 h (Cltot 16.7 ml/min) and the amount of excreted radioactivity was enhanced (26.3% of administered dose; Clren 4.5 ml/min) as compared with the data of PHY without co-medication.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],16.7,11694,DB00946,Phenprocoumon
,6534380,Clren,Under the co-administration of PPC the vitamin was eliminated with a half-life time of 23.1 h (Cltot 16.7 ml/min) and the amount of excreted radioactivity was enhanced (26.3% of administered dose; Clren 4.5 ml/min) as compared with the data of PHY without co-medication.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],4.5,11695,DB00946,Phenprocoumon
,2901471,clearance,"A significantly lower clearance was found in female than in male rats (7.9 +/- 1.4 vs 24.5 +/- 2.5 mL h-1 kg-1, respectively; t = 15.09, P less than 0.001) as well as a lower apparent volume of distribution (288 +/- 46 vs 617 +/- 105 mL kg-1; t = 7.58, P less than 0.001) and a longer half-life (25.5 +/- 3.4 vs 17.5 +/- 1.8 h; t = 5.16, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ml] / [h·kg],7.9,24235,DB00946,Phenprocoumon
,2901471,clearance,"A significantly lower clearance was found in female than in male rats (7.9 +/- 1.4 vs 24.5 +/- 2.5 mL h-1 kg-1, respectively; t = 15.09, P less than 0.001) as well as a lower apparent volume of distribution (288 +/- 46 vs 617 +/- 105 mL kg-1; t = 7.58, P less than 0.001) and a longer half-life (25.5 +/- 3.4 vs 17.5 +/- 1.8 h; t = 5.16, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ml] / [h·kg],24.5,24236,DB00946,Phenprocoumon
,2901471,apparent volume of distribution,"A significantly lower clearance was found in female than in male rats (7.9 +/- 1.4 vs 24.5 +/- 2.5 mL h-1 kg-1, respectively; t = 15.09, P less than 0.001) as well as a lower apparent volume of distribution (288 +/- 46 vs 617 +/- 105 mL kg-1; t = 7.58, P less than 0.001) and a longer half-life (25.5 +/- 3.4 vs 17.5 +/- 1.8 h; t = 5.16, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ml] / [kg],288,24237,DB00946,Phenprocoumon
,2901471,apparent volume of distribution,"A significantly lower clearance was found in female than in male rats (7.9 +/- 1.4 vs 24.5 +/- 2.5 mL h-1 kg-1, respectively; t = 15.09, P less than 0.001) as well as a lower apparent volume of distribution (288 +/- 46 vs 617 +/- 105 mL kg-1; t = 7.58, P less than 0.001) and a longer half-life (25.5 +/- 3.4 vs 17.5 +/- 1.8 h; t = 5.16, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ml] / [kg],617,24238,DB00946,Phenprocoumon
,2901471,half-life,"A significantly lower clearance was found in female than in male rats (7.9 +/- 1.4 vs 24.5 +/- 2.5 mL h-1 kg-1, respectively; t = 15.09, P less than 0.001) as well as a lower apparent volume of distribution (288 +/- 46 vs 617 +/- 105 mL kg-1; t = 7.58, P less than 0.001) and a longer half-life (25.5 +/- 3.4 vs 17.5 +/- 1.8 h; t = 5.16, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),h,25.5,24239,DB00946,Phenprocoumon
,2901471,half-life,"A significantly lower clearance was found in female than in male rats (7.9 +/- 1.4 vs 24.5 +/- 2.5 mL h-1 kg-1, respectively; t = 15.09, P less than 0.001) as well as a lower apparent volume of distribution (288 +/- 46 vs 617 +/- 105 mL kg-1; t = 7.58, P less than 0.001) and a longer half-life (25.5 +/- 3.4 vs 17.5 +/- 1.8 h; t = 5.16, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),h,17.5,24240,DB00946,Phenprocoumon
,2901471,fu,"The binding of phenprocoumon was higher in female than in male rats (fu: 0.0096 +/ 0.0008 vs 0.0124 +/- 0.0007, respectively; t = 6.66, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),,0.0096,24241,DB00946,Phenprocoumon
,2901471,fu,"The binding of phenprocoumon was higher in female than in male rats (fu: 0.0096 +/ 0.0008 vs 0.0124 +/- 0.0007, respectively; t = 6.66, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),,0.0124,24242,DB00946,Phenprocoumon
,2901471,C50,"The total (C) as well as the unbound concentration (Cu) needed to elicit a 50% decrease in the prothrombin complex synthesis rate was substantially higher in female rats: C50 was 377 +/- 98 ng mL-1 in female and 155 +/- 29 ng mL-1 in male rats (t = 5.32, P less than 0.001), whereas Cu50 was 3.6 +/- 0.7 ng mL-1 in female and 1.9 +/- 0.3 ng mL-1 in male rats (t = 5.50, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ng] / [ml],377,24243,DB00946,Phenprocoumon
,2901471,C50,"The total (C) as well as the unbound concentration (Cu) needed to elicit a 50% decrease in the prothrombin complex synthesis rate was substantially higher in female rats: C50 was 377 +/- 98 ng mL-1 in female and 155 +/- 29 ng mL-1 in male rats (t = 5.32, P less than 0.001), whereas Cu50 was 3.6 +/- 0.7 ng mL-1 in female and 1.9 +/- 0.3 ng mL-1 in male rats (t = 5.50, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ng] / [ml],155,24244,DB00946,Phenprocoumon
,2901471,Cu50,"The total (C) as well as the unbound concentration (Cu) needed to elicit a 50% decrease in the prothrombin complex synthesis rate was substantially higher in female rats: C50 was 377 +/- 98 ng mL-1 in female and 155 +/- 29 ng mL-1 in male rats (t = 5.32, P less than 0.001), whereas Cu50 was 3.6 +/- 0.7 ng mL-1 in female and 1.9 +/- 0.3 ng mL-1 in male rats (t = 5.50, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ng] / [ml],3.6,24245,DB00946,Phenprocoumon
,2901471,Cu50,"The total (C) as well as the unbound concentration (Cu) needed to elicit a 50% decrease in the prothrombin complex synthesis rate was substantially higher in female rats: C50 was 377 +/- 98 ng mL-1 in female and 155 +/- 29 ng mL-1 in male rats (t = 5.32, P less than 0.001), whereas Cu50 was 3.6 +/- 0.7 ng mL-1 in female and 1.9 +/- 0.3 ng mL-1 in male rats (t = 5.50, P less than 0.001).",Sex-related differences in disposition and response to phenprocoumon in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901471/),[ng] / [ml],1.9,24246,DB00946,Phenprocoumon
,958506,serum half-life,"After the i.v. administration of 20 mg phenprocoumon in a single dose to 4 healthy volunteers the following pharmacokinetic data were obtained: After the initial fast decrease (phase 1) of the serum level of phenprocoumon, probably due to the distribution into the different compartments is followed by a subsequent slower fall (phase 2) which occurs with a serum half-life of 157 h.",Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/958506/),h,157,25318,DB00946,Phenprocoumon
,958506,apparent distribution volume,The apparent distribution volume was 6.51.,Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/958506/),,6.51,25319,DB00946,Phenprocoumon
,15315768,total run time,Chromatographic separation was achieved on a reversed-phase Luna C18 column and step gradient elution resulted in a total run time of about 13 min.,"Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),min,13,27254,DB00946,Phenprocoumon
<,15315768,limit of detection (LOD),Limits of quantification (LOQ) were < or = 40 nM for the parent compounds and < or = 25 nM for the metabolites and the limit of detection (LOD) was < or = 2.5 nM for all analytes.,"Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),nM,2.5,27255,DB00946,Phenprocoumon
,15315768,recovery,"Average recovery was 84% (+/- 3.7) and 74% (+/- 13.2) in plasma and urine, respectively.","Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),%,84,27256,DB00946,Phenprocoumon
,15315768,recovery,"Average recovery was 84% (+/- 3.7) and 74% (+/- 13.2) in plasma and urine, respectively.","Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),%,74,27257,DB00946,Phenprocoumon
,6661354,terminal half-life,"For each compound administered alone the plasma concentration-time profile was adequately fitted by a biexponential equation, with an average terminal half-life of 2.0 and 1.15 h for the administered vitamin K and its 2,3-epoxide respectively.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,2.0,42263,DB00946,Phenprocoumon
,6661354,terminal half-life,"For each compound administered alone the plasma concentration-time profile was adequately fitted by a biexponential equation, with an average terminal half-life of 2.0 and 1.15 h for the administered vitamin K and its 2,3-epoxide respectively.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,1.15,42264,DB00946,Phenprocoumon
,6661354,half-life,"Following pretreatment with phenprocoumon and after intravenous administration of vitamin K1, both the average half-life and area under the plasma concentration-time profile of vitamin K1 were marginally reduced to 1.5 h and 1.76 mg l-1 h respectively, while the plasma concentration of vitamin K1-2,3-epoxide was readily measurable and its half-life markedly prolonged to 14.7 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,1.5,42265,DB00946,Phenprocoumon
,6661354,area under the plasma concentration-time profile,"Following pretreatment with phenprocoumon and after intravenous administration of vitamin K1, both the average half-life and area under the plasma concentration-time profile of vitamin K1 were marginally reduced to 1.5 h and 1.76 mg l-1 h respectively, while the plasma concentration of vitamin K1-2,3-epoxide was readily measurable and its half-life markedly prolonged to 14.7 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),[h·mg] / [l],1.76,42266,DB00946,Phenprocoumon
,6661354,half-life,"Following pretreatment with phenprocoumon and after intravenous administration of vitamin K1, both the average half-life and area under the plasma concentration-time profile of vitamin K1 were marginally reduced to 1.5 h and 1.76 mg l-1 h respectively, while the plasma concentration of vitamin K1-2,3-epoxide was readily measurable and its half-life markedly prolonged to 14.7 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,14.7,42267,DB00946,Phenprocoumon
,6661354,half-life,"Following pretreatment with phenprocoumon and after oral administration of vitamin K1-2,3-epoxide, no vitamin K1 was detectable in plasma and the half-life of the epoxide was 13.8 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,13.8,42268,DB00946,Phenprocoumon
,2264055,plasma half-life (beta-phase),"The average plasma half-life (beta-phase) was 22 hours, the apparent volume of distribution was 0.61 l/kg, Cltot was 25.2 ml/kg/h (13.9-40.9 ml/kg/h).",[The treatment basis for anticoagulants in horses]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),h,22,64536,DB00946,Phenprocoumon
,2264055,apparent volume of distribution,"The average plasma half-life (beta-phase) was 22 hours, the apparent volume of distribution was 0.61 l/kg, Cltot was 25.2 ml/kg/h (13.9-40.9 ml/kg/h).",[The treatment basis for anticoagulants in horses]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),[l] / [kg],0.61,64537,DB00946,Phenprocoumon
,2264055,Cltot,"The average plasma half-life (beta-phase) was 22 hours, the apparent volume of distribution was 0.61 l/kg, Cltot was 25.2 ml/kg/h (13.9-40.9 ml/kg/h).",[The treatment basis for anticoagulants in horses]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),[ml] / [h·kg],25.2,64538,DB00946,Phenprocoumon
,2264055,systemic bioavailability,"The systemic bioavailability of oral phenprocoumon was 97.6%, Tmax was found to be 4-12 hours.",[The treatment basis for anticoagulants in horses]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),%,97.6,64539,DB00946,Phenprocoumon
,2264055,Tmax,"The systemic bioavailability of oral phenprocoumon was 97.6%, Tmax was found to be 4-12 hours.",[The treatment basis for anticoagulants in horses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),h,4-12,64540,DB00946,Phenprocoumon
,23519598,clearance fractions,"Phenprocoumon clearance fractions mediated per CYP2C9 allele were 13.4, 9.5 and 5.7 mL/h for the 1, 2 and 3 variants, respectively.",Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23519598/),[ml] / [h],13.4,82210,DB00946,Phenprocoumon
,23519598,clearance fractions,"Phenprocoumon clearance fractions mediated per CYP2C9 allele were 13.4, 9.5 and 5.7 mL/h for the 1, 2 and 3 variants, respectively.",Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23519598/),[ml] / [h],9.5,82211,DB00946,Phenprocoumon
,23519598,clearance fractions,"Phenprocoumon clearance fractions mediated per CYP2C9 allele were 13.4, 9.5 and 5.7 mL/h for the 1, 2 and 3 variants, respectively.",Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23519598/),[ml] / [h],5.7,82212,DB00946,Phenprocoumon
,23519598,clearance fraction,An additional clearance fraction of 5.3 mL/h was independent of CYP2C9 activity.,Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23519598/),[ml] / [h],5.3,82213,DB00946,Phenprocoumon
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,12.7,90690,DB00946,Phenprocoumon
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,15.5,90691,DB00946,Phenprocoumon
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],40.9,90692,DB00946,Phenprocoumon
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],33.9,90693,DB00946,Phenprocoumon
,8032579,t1/2 alpha,"The following mean data were obtained after i.v. injection:t1/2 alpha 0.432h, t1/2 beta 128 h, co 0.651 microgram/ml, Vd 14.41,AUCo-omega 121 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),h,0.432,97133,DB00946,Phenprocoumon
,8032579,t1/2 beta,"The following mean data were obtained after i.v. injection:t1/2 alpha 0.432h, t1/2 beta 128 h, co 0.651 microgram/ml, Vd 14.41,AUCo-omega 121 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),h,128,97134,DB00946,Phenprocoumon
,8032579,co,"The following mean data were obtained after i.v. injection:t1/2 alpha 0.432h, t1/2 beta 128 h, co 0.651 microgram/ml, Vd 14.41,AUCo-omega 121 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[μg] / [ml],0.651,97135,DB00946,Phenprocoumon
,8032579,Vd,"The following mean data were obtained after i.v. injection:t1/2 alpha 0.432h, t1/2 beta 128 h, co 0.651 microgram/ml, Vd 14.41,AUCo-omega 121 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),,14.41,97136,DB00946,Phenprocoumon
,8032579,AUCo-omega,"The following mean data were obtained after i.v. injection:t1/2 alpha 0.432h, t1/2 beta 128 h, co 0.651 microgram/ml, Vd 14.41,AUCo-omega 121 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[h·μg] / [ml],121,97137,DB00946,Phenprocoumon
,8032579,tmax,"After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),h,2.25,97138,DB00946,Phenprocoumon
,8032579,Cmax,"After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[μg] / [ml],1.01,97139,DB00946,Phenprocoumon
,8032579,tabs,"After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),h,0.553,97140,DB00946,Phenprocoumon
,8032579,co,"After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[μg] / [ml],0.865,97141,DB00946,Phenprocoumon
,8032579,t1/2 beta,"After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),h,132,97142,DB00946,Phenprocoumon
,8032579,AUC0-infinity,"After intake of 9 mg PPC the following mean values were measured: tmax 2.25 h, Cmax 1.01 micrograms/ml, tabs 0.553 h, co 0.865 micrograms/ml, t1/2 beta 132 h, AUC0-infinity 164 micrograms x h/ml.",Pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[h·μg] / [ml],164,97143,DB00946,Phenprocoumon
,8032579,clearance,"By comparison of the PPC plasma level with the corresponding urinary excretion, a total mean PPC clearance of 20.0 (i.v.) and 15.1 (per os) ml/h was calculated within the first 8 h post dose, while the values measured did not differ between 8 and 48 h post dose (14.8 vs 15.3 ml/h).",Pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[ml] / [h],20.0,97144,DB00946,Phenprocoumon
,8032579,clearance,"By comparison of the PPC plasma level with the corresponding urinary excretion, a total mean PPC clearance of 20.0 (i.v.) and 15.1 (per os) ml/h was calculated within the first 8 h post dose, while the values measured did not differ between 8 and 48 h post dose (14.8 vs 15.3 ml/h).",Pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[ml] / [h],15.1,97145,DB00946,Phenprocoumon
,8032579,clearance,"By comparison of the PPC plasma level with the corresponding urinary excretion, a total mean PPC clearance of 20.0 (i.v.) and 15.1 (per os) ml/h was calculated within the first 8 h post dose, while the values measured did not differ between 8 and 48 h post dose (14.8 vs 15.3 ml/h).",Pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[ml] / [h],14.8,97146,DB00946,Phenprocoumon
,8032579,clearance,"By comparison of the PPC plasma level with the corresponding urinary excretion, a total mean PPC clearance of 20.0 (i.v.) and 15.1 (per os) ml/h was calculated within the first 8 h post dose, while the values measured did not differ between 8 and 48 h post dose (14.8 vs 15.3 ml/h).",Pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032579/),[ml] / [h],15.3,97147,DB00946,Phenprocoumon
,2778004,limit of detection,"The limit of detection (50 and 80 ng/ml) and precision (less than 5%) of the method are adequate for pharmacokinetic and enantioselective disposition studies, respectively, of phenprocoumon.",Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778004/),[ng] / [ml],50,105100,DB00946,Phenprocoumon
,2778004,limit of detection,"The limit of detection (50 and 80 ng/ml) and precision (less than 5%) of the method are adequate for pharmacokinetic and enantioselective disposition studies, respectively, of phenprocoumon.",Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778004/),[ng] / [ml],80,105101,DB00946,Phenprocoumon
,17688,biologic half-life,The mean biologic half-life of the S(-)-enantiomer was shorter (12-5 h) than that of R(+)-phenprocoumon (17-8 h).,Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688/),h,12-5,116962,DB00946,Phenprocoumon
,17688,biologic half-life,The mean biologic half-life of the S(-)-enantiomer was shorter (12-5 h) than that of R(+)-phenprocoumon (17-8 h).,Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688/),h,17-8,116963,DB00946,Phenprocoumon
,25308231,VK1,"Additionally, the increases in VK1 concentrations were similar (tablets, 3.2 μg L(-1) ; solution, 3.4 μg L(-1) ; P = 0.99) after 24 h.",Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308231/),[μg] / [l],3.2,126411,DB00946,Phenprocoumon
,25308231,VK1,"Additionally, the increases in VK1 concentrations were similar (tablets, 3.2 μg L(-1) ; solution, 3.4 μg L(-1) ; P = 0.99) after 24 h.",Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308231/),[μg] / [l],3.4,126412,DB00946,Phenprocoumon
,2257863,AUC,"Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.",The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257863/),μg,295,163054,DB00946,Phenprocoumon
,2257863,AUC,"Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.",The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257863/),μg,157,163055,DB00946,Phenprocoumon
,9143864,total plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[μg] / [ml],2.19,163446,DB00946,Phenprocoumon
,9143864,total plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[μg] / [ml],2.43,163447,DB00946,Phenprocoumon
,9143864,percentage unbound drug in the plasma,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),%,0.61,163448,DB00946,Phenprocoumon
,9143864,percentage unbound drug in the plasma,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),%,0.64,163449,DB00946,Phenprocoumon
,9143864,unbound plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),ng,13.8,163450,DB00946,Phenprocoumon
,9143864,unbound plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),ng,15.1,163451,DB00946,Phenprocoumon
,9143864,metabolic clearance based on unbound drug,"However, the older patients had an about 30% significantly lower metabolic clearance based on unbound drug (84 vs. 115 ml.kg-1.h-1).",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[ml] / [h·kg],84,163452,DB00946,Phenprocoumon
,9143864,metabolic clearance based on unbound drug,"However, the older patients had an about 30% significantly lower metabolic clearance based on unbound drug (84 vs. 115 ml.kg-1.h-1).",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[ml] / [h·kg],115,163453,DB00946,Phenprocoumon
,6714293,total body clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],1.64,168572,DB00946,Phenprocoumon
,6714293,total body clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],0.90,168573,DB00946,Phenprocoumon
,6714293,free drug clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],144,168574,DB00946,Phenprocoumon
,6714293,free drug clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],113,168575,DB00946,Phenprocoumon
,6714293,clearance,In contrast the clearance of antipyrine was much reduced in the cirrhotic group (17.5 +/- 2.9 ml/h/kg) compared with normal (35.6 +/- 3.9 ml/h/kg).,The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],17.5,168576,DB00946,Phenprocoumon
,6714293,clearance,In contrast the clearance of antipyrine was much reduced in the cirrhotic group (17.5 +/- 2.9 ml/h/kg) compared with normal (35.6 +/- 3.9 ml/h/kg).,The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],35.6,168577,DB00946,Phenprocoumon
,7874369,plasma concentrations,"Phenprocoumon plasma concentrations came to 1.38 +/- 0.28 micrograms/ml on day 12 to 15 and were not significantly altered under flupirtine coadministration with 1.48 +/- 0.36 micrograms/ml on day 25 to 28 (95% confidence interval: 1.02-1.11, point estimator: 1.06).",Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874369/),[μg] / [ml],1.38,187445,DB00946,Phenprocoumon
,7874369,plasma concentrations,"Phenprocoumon plasma concentrations came to 1.38 +/- 0.28 micrograms/ml on day 12 to 15 and were not significantly altered under flupirtine coadministration with 1.48 +/- 0.36 micrograms/ml on day 25 to 28 (95% confidence interval: 1.02-1.11, point estimator: 1.06).",Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874369/),μ,1.48,187446,DB00946,Phenprocoumon
,7874369,Quick time,The average Quick time came to 68 +/- 10% on day 12-15 and 73 +/- 15% on day 25-28.,Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874369/),%,68,187447,DB00946,Phenprocoumon
,7874369,Quick time,The average Quick time came to 68 +/- 10% on day 12-15 and 73 +/- 15% on day 25-28.,Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874369/),%,73,187448,DB00946,Phenprocoumon
,7874369,Protein binding,Protein binding of phenprocoumon was determined to 88.8% +/- 0.5 on day 14 and to 88.9 +/- 0.5% on day 28.,Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874369/),%,88.8,187449,DB00946,Phenprocoumon
,7874369,Protein binding,Protein binding of phenprocoumon was determined to 88.8% +/- 0.5 on day 14 and to 88.9 +/- 0.5% on day 28.,Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874369/),%,88.9,187450,DB00946,Phenprocoumon
,2390422,clearance,3. Administration of OCS was associated with a significant increase in the clearance of phenprocoumon from 1.6 +/- 0.7 to 2.0 +/- 0.7 ml min-1 kg-1 (P less than 0.05).,Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390422/),[ml] / [kg·min],1.6,195325,DB00946,Phenprocoumon
,2390422,clearance,3. Administration of OCS was associated with a significant increase in the clearance of phenprocoumon from 1.6 +/- 0.7 to 2.0 +/- 0.7 ml min-1 kg-1 (P less than 0.05).,Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390422/),[ml] / [kg·min],2.0,195326,DB00946,Phenprocoumon
,2390422,urinary recovery,The urinary recovery of phenprocoumon glucuronide was significantly higher in OCS users (21.0 +/- 16 vs 14.0 +/- 10 (% of dose); P less than 0.05).,Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390422/),%·dose,21.0,195327,DB00946,Phenprocoumon
,2390422,urinary recovery,The urinary recovery of phenprocoumon glucuronide was significantly higher in OCS users (21.0 +/- 16 vs 14.0 +/- 10 (% of dose); P less than 0.05).,Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390422/),%·dose,14.0,195328,DB00946,Phenprocoumon
,2390422,plasma protein binding,"No difference in plasma protein binding of phenprocoumon was observed, being 99.2 +/- 0.07 in both groups.",Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390422/),,99.2,195329,DB00946,Phenprocoumon
,3694526,distribution,"When administered in microdoses (9 micrograms i.v.) to rats (male Wistars, 270-300 g), a steep distribution phase (T1/2 = 0.25 hr) was followed by a relatively slow beta-phase (T1/2 = 40 hr).","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,0.25,201486,DB00946,Phenprocoumon
,3694526,beta-phase (T1/2,"When administered in microdoses (9 micrograms i.v.) to rats (male Wistars, 270-300 g), a steep distribution phase (T1/2 = 0.25 hr) was followed by a relatively slow beta-phase (T1/2 = 40 hr).","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,40,201487,DB00946,Phenprocoumon
,3694526,volume of distribution,The observed volume of distribution was 390 ml.,"Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),ml,390,201488,DB00946,Phenprocoumon
,3694526,volume of distribution,"This pharmacokinetic behavior contrasted highly with the one seen for higher (greater than 0.2 mg/kg) doses (unlabeled) warfarin; volume of distribution = 45 ml, T1/2 = 12.5 hr.","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),ml,45,201489,DB00946,Phenprocoumon
,3694526,T1/2,"This pharmacokinetic behavior contrasted highly with the one seen for higher (greater than 0.2 mg/kg) doses (unlabeled) warfarin; volume of distribution = 45 ml, T1/2 = 12.5 hr.","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,12.5,201490,DB00946,Phenprocoumon
,3694526,rate of appearance,The rate of appearance of [14C]warfarin was 0.3 hr-1 irrespective the 4-hydroxycoumarin used.,"Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),1/[h],0.3,201491,DB00946,Phenprocoumon
,10027661,area under the concentration-time curve (AUC),Lornoxicam co-administration resulted in a statistically significant increase of the area under the concentration-time curve (AUC) of the more potent (S)-isomer of phenprocoumon from a median value of 100 (range 68-146) mg x h x 1(-1) to 124 (92-239) mg x h x 1(-1).,Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,100,208551,DB00946,Phenprocoumon
,10027661,area under the concentration-time curve (AUC),Lornoxicam co-administration resulted in a statistically significant increase of the area under the concentration-time curve (AUC) of the more potent (S)-isomer of phenprocoumon from a median value of 100 (range 68-146) mg x h x 1(-1) to 124 (92-239) mg x h x 1(-1).,Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,124,208552,DB00946,Phenprocoumon
,10027661,AUC,"For the (R)-isomer, the AUC increase from 96 (70-142) mg x h x 1(-1) in the absence to 108 (75-155) mg x h x 1(-1) in the presence of lornoxicam was not statistically significant.",Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,96,208553,DB00946,Phenprocoumon
,10027661,AUC,"For the (R)-isomer, the AUC increase from 96 (70-142) mg x h x 1(-1) in the absence to 108 (75-155) mg x h x 1(-1) in the presence of lornoxicam was not statistically significant.",Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,108,208554,DB00946,Phenprocoumon
,9483171,plasma half-life,The plasma half-life of phenprocoumon was approximately 350 h (normal 120-150 h).,Vitamin K metabolism in a patient resistant to vitamin K antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483171/),h,350,209422,DB00946,Phenprocoumon
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],1.96,213259,DB00946,Phenprocoumon
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],2.58,213260,DB00946,Phenprocoumon
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,1.2,214118,DB00946,Phenprocoumon
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,5.5,214119,DB00946,Phenprocoumon
,11765590,CL/f,"Pharmacokinetic parameters of phenprocoumon following oral administration were: CL/f: 0.779 +/- 0.157 ml/min, half-life of elimination: 147.2 +/- 19.9 h; free fraction in serum: 0.51 +/- 0.20%.",Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),[ml] / [min],0.779,240273,DB00946,Phenprocoumon
,11765590,half-life of elimination,"Pharmacokinetic parameters of phenprocoumon following oral administration were: CL/f: 0.779 +/- 0.157 ml/min, half-life of elimination: 147.2 +/- 19.9 h; free fraction in serum: 0.51 +/- 0.20%.",Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),h,147.2,240274,DB00946,Phenprocoumon
,11765590,free fraction in serum,"Pharmacokinetic parameters of phenprocoumon following oral administration were: CL/f: 0.779 +/- 0.157 ml/min, half-life of elimination: 147.2 +/- 19.9 h; free fraction in serum: 0.51 +/- 0.20%.",Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),%,0.51,240275,DB00946,Phenprocoumon
,11765590,Prothrombin time,Prothrombin time increased from 13.3 +/- 1.3 s (at time 0) to 17.7 +/- 2.7 s following phenprocoumon and from 13.3 +/- 1.2 s to 18.0 +/- 2.2 s following combined administration.,Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),s,13.3,240276,DB00946,Phenprocoumon
,11765590,Prothrombin time,Prothrombin time increased from 13.3 +/- 1.3 s (at time 0) to 17.7 +/- 2.7 s following phenprocoumon and from 13.3 +/- 1.2 s to 18.0 +/- 2.2 s following combined administration.,Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),s,17.7,240277,DB00946,Phenprocoumon
,11765590,Prothrombin time,Prothrombin time increased from 13.3 +/- 1.3 s (at time 0) to 17.7 +/- 2.7 s following phenprocoumon and from 13.3 +/- 1.2 s to 18.0 +/- 2.2 s following combined administration.,Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),s,13.3,240278,DB00946,Phenprocoumon
,11765590,Prothrombin time,Prothrombin time increased from 13.3 +/- 1.3 s (at time 0) to 17.7 +/- 2.7 s following phenprocoumon and from 13.3 +/- 1.2 s to 18.0 +/- 2.2 s following combined administration.,Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),s,18.0,240279,DB00946,Phenprocoumon
,11765590,integrated effect (AUEC0-288 h,"The integrated effect (AUEC0-288 h) was identical following both treatments (4.303 +/- 461 and 4.303 +/- 312 s x h for phenprocoumon alone and phenprocoumon with lysine clonixinate, respectively).",Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),h·s,4.303,240280,DB00946,Phenprocoumon
,11765590,integrated effect (AUEC0-288 h,"The integrated effect (AUEC0-288 h) was identical following both treatments (4.303 +/- 461 and 4.303 +/- 312 s x h for phenprocoumon alone and phenprocoumon with lysine clonixinate, respectively).",Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765590/),h·s,4.303,240281,DB00946,Phenprocoumon
,2459009,steady-state plasma PPC concentrations,"As predicted by the model, in 72% of the patients the average steady-state plasma PPC concentrations were within the range of 1.7 and 2.3 micrograms/ml.",Adjustment of phenprocoumon dosage utilizing a pharmacokinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459009/),[μg] / [ml],1.7,245836,DB00946,Phenprocoumon
,2459009,steady-state plasma PPC concentrations,"As predicted by the model, in 72% of the patients the average steady-state plasma PPC concentrations were within the range of 1.7 and 2.3 micrograms/ml.",Adjustment of phenprocoumon dosage utilizing a pharmacokinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459009/),[μg] / [ml],2.3,245837,DB00946,Phenprocoumon
